Beil W, Sewing K F
Institut für Allgemeine Pharmakologie, Medizinische Hochschule Hannover.
Z Gastroenterol. 1993 Nov;31(11):643-5.
Some histamine-H2-receptor antagonists block gastric first-pass metabolism of ethanol and lead to increased blood alcohol concentrations after ingestion of a low dose (0.15 and 0.3 g/kg) of alcohol. To investigate whether the histamine-H2-receptor antagonist roxatidine acetate has a similar effect, we administered a low dose (0.3 g/kg) of ethanol to eleven volunteers before and after seven days treatment with roxatidine acetate (150 mg once daily). No effect of the drug on mean peak serum alcohol concentrations or on areas under the serum alcohol curves was found. In vitro, roxatidine acetate and its active metabolite roxatidine had almost no effect on guinea-pig gastric alcohol dehydrogenase activity. We conclude that roxatidine acetate does not block gastric first-pass metabolism of ethanol and can be considered as a safe histamine-H2-receptor antagonist in individuals who do not refrain from alcohol consumption under treatment for gastric or duodenal ulcer disease.
一些组胺H2受体拮抗剂可阻断乙醇的胃首过代谢,并在摄入低剂量(0.15和0.3 g/kg)酒精后导致血中酒精浓度升高。为研究组胺H2受体拮抗剂醋酸罗沙替丁是否有类似作用,我们在11名志愿者接受醋酸罗沙替丁(150 mg,每日1次)治疗7天前后,给他们服用低剂量(0.3 g/kg)的乙醇。未发现该药物对平均血清酒精峰值浓度或血清酒精曲线下面积有影响。在体外,醋酸罗沙替丁及其活性代谢产物罗沙替丁对豚鼠胃酒精脱氢酶活性几乎没有影响。我们得出结论,醋酸罗沙替丁不会阻断乙醇的胃首过代谢,对于在治疗胃或十二指肠溃疡疾病期间不禁酒的个体,可将其视为一种安全的组胺H2受体拮抗剂。